CD19 modulators(B-lymphocyte antigen CD19 modulators), CD28 modulators(T-cell-specific surface glycoprotein CD28 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

B-Cell Malignant NeoplasmB-Cell LeukemiaCD19 positive B-Cell Lymphoma+ [1]

Inactive Indication-

Originator Organization

CytoCares Shanghai, Inc.Startup

Active Organization

CytoCares Shanghai, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Clinical Trials associated with CC-312

NCT06037018 / RecruitingPhase 1

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Efficacy of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell non-Hodgkin lymphoma and B-cell lymphocytic leukemia.

Start Date07 Aug 2023

Sponsor / Collaborator

CytoCares Shanghai, Inc.Startup

CTR20232114 / RecruitingPhase 1

一项评价CC312在复发/难治性CD19阳性B细胞恶性血液肿瘤成年患者的安全耐受性、药代动力学（PK）、药效动力学（PD）、免疫原性及初步抗肿瘤活性的多中心I期临床研究

[Translation] A multicenter Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and preliminary anti-tumor activity of CC312 in adult patients with relapsed/refractory CD19-positive B-cell hematological malignancies

（1）评估CC312在复发/难治性CD19阳性的B细胞性非霍奇金淋巴瘤和B淋巴细胞白血病患者中的安全性和耐受性；（2）探索CC312的剂量限制性毒性（DLT），并确定CC312在复发/难治CD19阳性的B细胞性非霍奇金淋巴瘤患者中的最大耐受剂量（MTD）和/或II期推荐剂量（RP2D）。

[Translation]

(1) Evaluate the safety and tolerability of CC312 in patients with relapsed/refractory CD19-positive B-cell non-Hodgkin's lymphoma and B-cell leukemia; (2) Explore the dose-limiting toxicity (DLT) of CC312 and determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D) of CC312 in patients with relapsed/refractory CD19-positive B-cell non-Hodgkin's lymphoma.

Start Date25 Jul 2023

Sponsor / Collaborator

CytoCares Shanghai, Inc.Startup

100 Clinical Results associated with CC-312

100 Translational Medicine associated with CC-312

100 Patents (Medical) associated with CC-312

Literatures (Medical) associated with CC-312

01 Jun 2005·Journal of Immunological MethodsQ4 · MEDICINE

Development of detection methods for ruminant interleukin (IL)-4

Q4 · MEDICINE

Article

Author: Sopp, P. ; Palmer, G. H. ; Kwong, L. S. ; Mwangi, W. ; Brown, W. C. ; Howard, C. J. ; Entrican, G. ; Thom, M. ; Wattegedera, S. ; Hope, J. C.

Recombinant bovine IL-4 (rbo IL-4) was transiently expressed in COS-7 cells. Mice were immunised with a plasmid encoding rbo IL-4 and boosted with rbo IL-4. A number of monoclonal antibodies (mAb) were generated that reacted with rbo IL-4 in an ELISA and these cloned hybridomas were termed CC311, CC312, CC313 and CC314. A pair of mAb (CC313 and CC314) was identified that together could be used to detect both recombinant and native bovine IL-4 by ELISA and a luminometric detection method was applied to the ELISA. Using this method native bovine IL-4 was detected in supernatants of PBMC stimulated with mitogens. In addition, high level secretion of IL-4 by Fasciola hepatica specific Th2 clones, but not by a Babesia bovis specific Th1 clone, was confirmed. The ELISA was also able to detect recombinant ovine IL-4. The pair of mAb used for ELISA could also be used for the detection of IL-4 spot forming cells by ELISPOT. In addition intracytoplasmic expression of IL-4 could be detected. The ability to detect ruminant IL-4 by three methods: ELISA, ELISPOT and by flow cytometric analysis of intracytoplasmic expression will permit studies of the role of this important cytokine in the immunology and pathogenesis of animal diseases.

100 Deals associated with CC-312

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-Cell Malignant Neoplasm	Phase 1	CN	CytoCares Shanghai, Inc.Startup	07 Aug 2023
B-Cell Leukemia	Phase 1	CN	CytoCares Shanghai, Inc.Startup	25 Jul 2023
CD19 positive B-Cell Lymphoma	Phase 1	CN	CytoCares Shanghai, Inc.Startup	25 Jul 2023
Systemic Lupus Erythematosus	IND Approval	CN	CytoCares Shanghai, Inc.Startup	08 Aug 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CC-312

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation